BillionToOne announces IPO roadshow for 3.8 million shares of Class A common stock, priced between $49 and $55.
Quiver AI Summary
BillionToOne, Inc., a molecular diagnostics company based in Menlo Park, California, has announced the launch of its roadshow for a proposed initial public offering (IPO) of 3,846,000 shares of Class A common stock. The company plans to grant underwriters a 30-day option to purchase an additional 576,900 shares at the IPO price, which is expected to range from $49.00 to $55.00 per share. BillionToOne aims to list its shares on the Nasdaq Global Select Market under the ticker “BLLN.” J.P. Morgan, Piper Sandler, Jefferies, and William Blair are serving as joint book-running managers for the offering, with additional support from Stifel, Wells Fargo Securities, and BTIG. A registration statement related to the IPO has been filed with the U.S. Securities and Exchange Commission but is not yet effective, and no shares can be sold until it is approved.
Potential Positives
- BillionToOne has launched the roadshow for its proposed initial public offering (IPO), a significant step in the process of going public and potentially accessing greater capital.
- The proposed IPO includes the offering of 3,846,000 shares, with an additional option for underwriters to purchase up to 576,900 shares, indicating strong interest and demand for the company's equity.
- The expected initial public offering price of between $49.00 and $55.00 per share suggests a potentially favorable market valuation for the company.
- BillionToOne has chosen reputable joint book-running managers, including J.P. Morgan and Jefferies, which can enhance credibility and investor confidence in the offering.
Potential Negatives
- The press release indicates that the company's initial public offering (IPO) is contingent upon the effectiveness of their registration statement, which has not yet been approved, introducing uncertainty regarding the offering.
- The pricing of the IPO shares is quite high, with an expected range of $49.00 to $55.00, which may deter potential investors concerned about market conditions and stock valuation.
- The reliance on multiple joint book-running managers highlights a substantial level of dependence on external entities, which may raise concerns about the company's ability to independently manage its financial strategy.
FAQ
What is BillionToOne's IPO date?
BillionToOne has announced the launch of its roadshow for its initial public offering, but a specific date for the IPO has not been provided.
How many shares is BillionToOne offering?
BillionToOne is proposing an initial public offering of 3,846,000 shares of its Class A common stock.
What is the expected IPO price range for BillionToOne?
The initial public offering price for BillionToOne is expected to be between $49.00 and $55.00 per share.
Where will BillionToOne's shares be listed?
BillionToOne intends to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “BLLN.”
Who are the underwriters for BillionToOne's IPO?
The joint book-running managers for the proposed offering include J.P. Morgan, Piper Sandler, Jefferies, and William Blair.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has launched the roadshow for its proposed initial public offering of 3,846,000 shares of its Class A common stock. In addition, BillionToOne intends to grant the underwriters a 30-day option to purchase up to an additional 576,900 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions. The initial public offering price is currently expected to be between $49.00 and $55.00 per share. BillionToOne has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol “BLLN.”
J.P. Morgan, Piper Sandler, Jefferies and William Blair are acting as joint book-running managers for the proposed offering. Stifel, Wells Fargo Securities and BTIG are also acting as book-running managers for the proposed offering.
The proposed offering will be made only by means of a prospectus. Copies of the preliminary prospectus may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: [email protected] and [email protected] ; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, by telephone at (800) 747-3924, or by email at [email protected] ; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected] ; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at [email protected] .
A registration statement on Form S-1 related to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.
Media Contact
[email protected]
